| Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors SI Li, N Siriwon, X Zhang, S Yang, T Jin, F He, YJ Kim, J Mac, Z Lu, ... Clinical cancer research 23 (22), 6982-6992, 2017 | 283 | 2017 |
| Long-read sequencing and de novo assembly of a Chinese genome L Shi, Y Guo, C Dong, J Huddleston, H Yang, X Han, A Fu, Q Li, N Li, ... Nature communications 7 (1), 12065, 2016 | 283 | 2016 |
| Masked chimeric antigen receptor for tumor-specific activation X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang Molecular Therapy 25 (1), 274-284, 2017 | 98 | 2017 |
| In vivo expansion and antitumor activity of coinfused CD28-and 4-1BB-engineered CAR-T cells in patients with B cell leukemia Z Cheng, R Wei, Q Ma, L Shi, F He, Z Shi, T Jin, R Xie, B Wei, J Chen, ... Molecular Therapy 26 (4), 976-985, 2018 | 82 | 2018 |
| Adnectin-based design of chimeric antigen receptor for T cell engineering X Han, GE Cinay, Y Zhao, Y Guo, X Zhang, P Wang Molecular Therapy 25 (11), 2466-2476, 2017 | 65 | 2017 |
| Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth PD Bryson, X Han, N Truong, P Wang Vaccine 35 (43), 5842-5849, 2017 | 23 | 2017 |
| Dendritic cell-targeted lentiviral vector vaccines overcome tolerance to generate a protective T-cell immune response to breast cancer antigens ERBB2 and α-lactalbumin PD Bryson, X Han, N Truong, P Wang Cancer Research 74 (19_Supplement), 2888-2888, 2014 | | 2014 |
